2017 Q1 Form 10-Q Financial Statement
#000156459017008822 Filed on May 04, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $303.7M | $236.7M |
| YoY Change | 28.31% | 16.66% |
| Cost Of Revenue | $50.01M | $43.12M |
| YoY Change | 15.97% | 39.1% |
| Gross Profit | $253.7M | $193.6M |
| YoY Change | 31.05% | 12.62% |
| Gross Profit Margin | 83.54% | 81.79% |
| Selling, General & Admin | $120.0M | $105.3M |
| YoY Change | 13.98% | 13.46% |
| % of Gross Profit | 47.3% | 54.39% |
| Research & Development | $145.0M | $158.8M |
| YoY Change | -8.68% | 11.77% |
| % of Gross Profit | 57.15% | 82.01% |
| Depreciation & Amortization | $19.41M | $18.73M |
| YoY Change | 3.66% | 73.12% |
| % of Gross Profit | 7.65% | 9.67% |
| Operating Expenses | $265.0M | $264.1M |
| YoY Change | 0.35% | 12.44% |
| Operating Profit | -$20.21M | -$80.92M |
| YoY Change | -75.03% | 22.86% |
| Interest Expense | $10.12M | $9.843M |
| YoY Change | 2.8% | 4.03% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $3.500M | $200.0K |
| YoY Change | 1650.0% | 0.0% |
| Pretax Income | -$24.31M | -$89.13M |
| YoY Change | -72.73% | 19.31% |
| Income Tax | -$8.016M | -$6.075M |
| % Of Pretax Income | ||
| Net Earnings | -$16.29M | -$83.05M |
| YoY Change | -80.39% | 23.04% |
| Net Earnings / Revenue | -5.36% | -35.08% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$94.38K | -$514.6K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 172.9M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $678.1M | $456.9M |
| YoY Change | 48.41% | -54.7% |
| Cash & Equivalents | $348.2M | $270.5M |
| Short-Term Investments | $329.8M | $186.4M |
| Other Short-Term Assets | $60.30M | $58.20M |
| YoY Change | 3.61% | -49.61% |
| Inventory | $384.1M | $297.0M |
| Prepaid Expenses | ||
| Receivables | $230.3M | $180.8M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $1.353B | $992.8M |
| YoY Change | 36.26% | -34.8% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $824.0M | $725.1M |
| YoY Change | 13.64% | 34.75% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $533.6M | $314.4M |
| YoY Change | 69.72% | 39.86% |
| Other Assets | $485.0M | $260.5M |
| YoY Change | 86.18% | 6.89% |
| Total Long-Term Assets | $2.586B | $2.674B |
| YoY Change | -3.31% | 25.2% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.353B | $992.8M |
| Total Long-Term Assets | $2.586B | $2.674B |
| Total Assets | $3.939B | $3.667B |
| YoY Change | 7.41% | 0.23% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $146.6M | $145.9M |
| YoY Change | 0.48% | 518.06% |
| Accrued Expenses | $110.8M | $111.3M |
| YoY Change | -0.45% | 4.54% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $22.50M | |
| YoY Change | ||
| Total Short-Term Liabilities | $340.2M | $388.0M |
| YoY Change | -12.32% | 27.01% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $668.4M | $668.0M |
| YoY Change | 0.06% | 1.91% |
| Other Long-Term Liabilities | $160.9M | $177.2M |
| YoY Change | -9.2% | 124.3% |
| Total Long-Term Liabilities | $829.3M | $845.2M |
| YoY Change | -1.88% | 15.07% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $340.2M | $388.0M |
| Total Long-Term Liabilities | $829.3M | $845.2M |
| Total Liabilities | $1.170B | $1.377B |
| YoY Change | -15.06% | 11.64% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $2.769B | $2.290B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $3.939B | $3.667B |
| YoY Change | 7.41% | 0.23% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$16.29M | -$83.05M |
| YoY Change | -80.39% | 23.04% |
| Depreciation, Depletion And Amortization | $19.41M | $18.73M |
| YoY Change | 3.66% | 73.12% |
| Cash From Operating Activities | -$80.40M | -$171.5M |
| YoY Change | -53.12% | 24.46% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $69.09M | $45.20M |
| YoY Change | 52.84% | 3.13% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $1.391M | $150.0K |
| YoY Change | 827.33% | -85.39% |
| Cash From Investing Activities | $25.00M | $77.00M |
| YoY Change | -67.53% | -110.25% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -6.700M | -37.30M |
| YoY Change | -82.04% | -104.08% |
| NET CHANGE | ||
| Cash From Operating Activities | -80.40M | -171.5M |
| Cash From Investing Activities | 25.00M | 77.00M |
| Cash From Financing Activities | -6.700M | -37.30M |
| Net Change In Cash | -62.10M | -131.8M |
| YoY Change | -52.88% | -604.98% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$80.40M | -$171.5M |
| Capital Expenditures | $69.09M | $45.20M |
| Free Cash Flow | -$149.5M | -$216.7M |
| YoY Change | -31.02% | 19.31% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
303745000 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
236736000 | |
| CY2017Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
50006000 | |
| CY2016Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
43118000 | |
| CY2016Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1379000 | |
| CY2017Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1555000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
158793000 | |
| CY2017Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
120019000 | |
| CY2016Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
105300000 | |
| CY2016Q1 | bmrn |
Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
|
10442000 | |
| CY2017Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
323953000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
145003000 | |
| CY2017Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-10441000 | |
| CY2016Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-21368000 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
1730000 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
6526000 | |
| CY2017Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1353000 | |
| CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
2936000 | |
| CY2017Q1 | bmrn |
Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
|
8925000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
30177000 | |
| CY2017Q1 | us-gaap |
Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
|
3252000 | |
| CY2017Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-660000 | |
| CY2016Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-309000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
30674000 | |
| CY2016Q1 | us-gaap |
Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
|
0 | |
| CY2016Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
317653000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20208000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-80917000 | |
| CY2017Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-523000 | |
| CY2016Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-135000 | |
| CY2017Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3072000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1571000 | |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
10119000 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
9843000 | |
| CY2017Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
3472000 | |
| CY2016Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
198000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-24306000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-89126000 | |
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-8016000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-6075000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16290000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-83051000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.09 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.51 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
172710000 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
161548000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-24086000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-104037000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-7796000 | |
| CY2017Q1 | bmrn |
Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency
StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
|
4849000 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
|
6000 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
218000 | |
| CY2017Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
31523000 | |
| CY2017Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
19412000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
18726000 | |
| CY2017Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
7755000 | |
| CY2016Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
7337000 | |
| CY2017Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-969000 | |
| CY2016Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-526000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
14051000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
16044000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
22660000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
10285000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-2763000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-2399000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
527000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1232000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-77822000 | |
| CY2016Q1 | bmrn |
Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
|
4135000 | |
| CY2017Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-26297000 | |
| CY2016Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-14788000 | |
| CY2017Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
|
0 | |
| CY2017Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
2043000 | |
| CY2016Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
5132000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-60096000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-126587000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
397040000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
270453000 | |
| CY2017Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
6376000 | |
| CY2016Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
73215000 | |
| CY2017Q1 | bmrn |
Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
|
3226000 | |
| CY2016Q1 | bmrn |
Stock Based Compensation Capitalized
StockBasedCompensationCapitalized
|
2469000 | |
| CY2017Q1 | bmrn |
Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
|
5508000 | |
| CY2016Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
|
2436000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-90744000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
2744000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-4614000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-80443000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-171454000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
69090000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
45204000 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
149916000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
181267000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
54388000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
58914000 | |
| CY2017Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
1391000 | |
| CY2016Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
150000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
25047000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
76999000 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
13086000 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
3521000 | |
| CY2017Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
17935000 | |
| CY2016Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
40788000 | |
| CY2017Q1 | bmrn |
Payments Of Contingent Consideration
PaymentsOfContingentConsideration
|
1894000 | |
| CY2016Q1 | bmrn |
Payments Of Contingent Consideration
PaymentsOfContingentConsideration
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
0 | |
| CY2016Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
3000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-6743000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-37264000 | |
| CY2017Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS AND BUSINESS RISKS</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company), is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s therapy portfolio consists of six products and multiple clinical and pre-clinical product candidates. Brineura was granted marketing approval in the United States (U.S.) on April 27, 2017.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks, including: the financial performance of its commercial products; the potential need for additional financings; the Company’s ability to successfully commercialize its approved product candidates; the uncertainty of the Company’s research and development (R&D) efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry. </p></div> | |
| CY2017Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by the U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2017 or any other period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</p></div> | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
452000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3024000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
954058000 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22232000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
865418000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
503000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2472000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
863449000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
956630000 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22027000 | |
| CY2016 | bmrn |
Number Of Investments In Marketable Equity Securities
NumberOfInvestmentsInMarketableEquitySecurities
|
1 | |
| CY2017Q1 | us-gaap |
Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
|
3300000 | |
| CY2016Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
4100000 | |
| CY2016 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
2300000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
329821000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
381347000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
533628000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
572711000 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
863449000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
954058000 | |
| CY2017Q1 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
305122000 | |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
305122000 | |
| CY2017Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
332199000 | |
| CY2016Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
332199000 | |
| CY2017Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
637321000 | |
| CY2016Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
637321000 | |
| CY2017Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
91149000 | |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
83541000 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1182417000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1141362000 | |
| CY2017Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
358404000 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
342594000 | |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
17500000 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
15700000 | |
| CY2017Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
49871000 | |
| CY2016Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
51250000 | |
| CY2017Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
204379000 | |
| CY2016Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
167788000 | |
| CY2017Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
129893000 | |
| CY2016Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
136088000 | |
| CY2017Q1 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
9578000 | |
| CY2016Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
10722000 | |
| CY2017Q1 | us-gaap |
Investments
Investments
|
0 | |
| CY2016Q4 | us-gaap |
Investments
Investments
|
4064000 | |
| CY2017Q1 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
6030000 | |
| CY2016Q4 | us-gaap |
Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
|
8194000 | |
| CY2017Q1 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
10972000 | |
| CY2016Q4 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
9835000 | |
| CY2017Q1 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
135604000 | |
| CY2016Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
191353000 | |
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
60526000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
109038000 | |
| CY2017Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
36157000 | |
| CY2016Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
34737000 | |
| CY2017Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
14106000 | |
| CY2016Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
15151000 | |
| CY2017Q1 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
8178000 | |
| CY2016Q4 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
7848000 | |
| CY2017Q1 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
17876000 | |
| CY2016Q4 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
12378000 | |
| CY2017Q1 | us-gaap |
Convertible Debt
ConvertibleDebt
|
690932000 | |
| CY2015Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
683239000 | |
| CY2017Q1 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
965146000 | |
| CY2015Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
956933000 | |
| CY2017Q1 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
14722000 | |
| CY2017Q1 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
8720000 | |
| CY2016Q4 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
22206000 | |
| CY2016Q4 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
7543000 | |
| CY2017Q1 | us-gaap |
Asset Retirement Obligation
AssetRetirementObligation
|
4000000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
685870 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
36.23 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
30674000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
30177000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
3200000 | |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
2500000 | |
| CY2017Q1 | us-gaap |
Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
|
-2633000 | |
| CY2017Q1 | us-gaap |
Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
|
5768000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
|
-605000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-7796000 | |
| CY2016Q1 | us-gaap |
Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
|
-16157000 | |
| CY2016Q1 | us-gaap |
Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
|
7621000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
|
-2792000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-20986000 | |
| CY2017Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017Q1 | bmrn |
Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
|
581800000 | |
| CY2017Q1 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
161700000 | |
| CY2017Q1 | us-gaap |
Purchase Obligation
PurchaseObligation
|
94400000 |
